Across TCGA pan-cancer cohorts, MIR1915HG Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIR1915HG data layer compared with 29 for mass-spec protein.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MIR1915HG Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR1915HG expression acts as an unfavorable survival marker.
LIHC are the cancer types where MIR1915HG Mutation most reproducibly stratifies survival.